|
gptkbp:instanceOf
|
gptkb:brand
|
|
gptkbp:approvedBy
|
gptkb:FDA
1987
|
|
gptkbp:ATCCode
|
J01MA02
|
|
gptkbp:availableOn
|
gptkb:tablet
intravenous solution
oral suspension
|
|
gptkbp:brandFor
|
ciprofloxacin
|
|
gptkbp:contraindication
|
children (except specific cases)
hypersensitivity to quinolones
|
|
gptkbp:discoveredBy
|
gptkb:Bayer
|
|
gptkbp:drugClass
|
fluoroquinolone antibiotics
|
|
gptkbp:eliminationHalfLife
|
4 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:genericName
|
ciprofloxacin
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cipro
|
|
gptkbp:interactsWith
|
gptkb:theophylline
gptkb:warfarin
dairy products
antacids
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
gptkb:Bayer
|
|
gptkbp:riskFactor
|
gptkb:Clostridioides_difficile_infection
QT prolongation
tendinitis
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
tendon rupture
|
|
gptkbp:usedFor
|
skin infections
urinary tract infections
bacterial infections
gastrointestinal infections
respiratory tract infections
anthrax exposure
bone and joint infections
|
|
gptkbp:bfsParent
|
gptkb:Ciprofloxacin
|
|
gptkbp:bfsLayer
|
5
|